Patient Preferences for Tyrosine Kinase Inhibitor Treatments for EGFR Mutation Positive Metastatic NSCLC

被引：0
|
作者：
Bridges, J. [1 ]
De La Cruz, M. [2 ]
Pavilack, M. [3 ]
Flood, E. [2 ]
Janssen, E. [2 ]
Chehab, N. [3 ]
Fernandes, A. [3 ]
机构：
[1] Ohio State Univ, Coll Med, Dept Biomed Informat, Columbus, OH 43210 USA
[2] Icon, Gaithersburg, MD USA
[3] Astrazeneca, Med Affairs Oncol, Gaithersburg, MD USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
treatment preference; EGFR-TKI; NSCLC;
D O I：
10.1016/j.jtho.2018.08.288
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA10.01
引用
收藏
页码：S343 / S343
页数：1
相关论文
共 50 条
  • [31] Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma
    Eun Young Kim
    Arum Kim
    Gaeun Lee
    Hangsuck Lee
    Yoon Soo Chang
    BMC Cancer, 18
  • [32] Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma
    Kim, Eun Young
    Kim, Arum
    Lee, Gaeun
    Lee, Hangsuck
    Chang, Yoon Soo
    BMC CANCER, 2018, 18
  • [33] Outcomes of NSCLC patients with positive EGFR mutation
    Diver, Sarah
    Haris, Mohammed
    Khan, Shahul Leyakathali
    Kerr, Jane
    Edwards, Jane
    Munavvar, Mohammed
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [34] Active or Attractive? Oral Antiangiogenesis Therapy Plus EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant NSCLC
    Liao, Bin-Chi
    Yang, James Chih-Hsin
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (09) : 1426 - 1428
  • [35] TPX-0005 with an EGFR Tyrosine Kinase Inhibitor (TKI) Overcomes Innate Resistance in EGFR Mutant NSCLC
    Rosell, R.
    Karachaliou, N.
    Cui, J. J.
    Chaib, I.
    Berenguer, J.
    Bratch, J.
    Li, X.
    Yang, J.
    Drozdowskyj, A.
    Codony Servat, C.
    Codony Servat, J.
    Gimenez-Capitan, A.
    Viteri, S.
    Molina-Vila, M.
    Lopez-Vivanco, G.
    Vergnenegre, A.
    Sanchez-Torres, J. M.
    Provencio, M.
    De Marinis, F.
    Passaro, A.
    Carcereny, E.
    Reguart, N.
    Garcia Campelo, R.
    Ignatius Ou, S.
    Cardona, A.
    Cao, P.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2230 - S2230
  • [36] Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation-positive Lung Cancer
    Ogimoto, Tatsuya
    Ozasa, Hiroaki
    Tsuji, Takahiro
    Funazo, Tomoko
    Yamazoe, Masatoshi
    Hashimoto, Kentaro
    Yoshida, Hiroshi
    Hosoya, Kazutaka
    Ajimizu, Hitomi
    Nomizo, Takashi
    Yoshida, Hironori
    Hamaji, Masatsugu
    Menju, Toshi
    Yoshizawa, Akihiko
    Date, Hiroshi
    Hirai, Toyohiro
    MOLECULAR CANCER THERAPEUTICS, 2024, 23 (04) : 564 - 576
  • [37] Iterative Upgrading of Small Molecular Tyrosine Kinase Inhibitors for EGFR Mutation in NSCLC: Necessity and Perspective
    Zhu, Jing
    Yang, Qian
    Xu, Weiguo
    PHARMACEUTICS, 2021, 13 (09)
  • [38] Early or late EGFR tyrosine kinase inhibitor, which is better for survival? - Retrospective analysis of 228 Korean patients with advanced or metastatic NSCLC
    Kim, Min Kyoung
    Ryoo, Hun Mo
    Bae, Sung Hwa
    Lee, Kyung Hee
    Hyun, Myung Soo
    Lee, Kwan-Ho
    Chung, Jin-Hong
    Shin, Kyung-Chul
    Lee, Sun Ah
    Lee, Sang Chae
    Hyun, Dae Sung
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S290 - S290
  • [39] Spred-3 mutation and Ras/Raf/MAPK activation confer acquired resistance to EGFR tyrosine kinase inhibitor in an EGFR mutated NSCLC cell line
    He, Zhiyong
    Gong, Fusheng
    Liao, Jinrong
    Wang, Qiang
    Su, Ying
    Chen, Chao
    Lin, Jinghui
    Lin, Ren-Jang
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (04) : 2542 - 2555
  • [40] Panniculitis in a patient with metastatic renal cell carcinoma on a tyrosine kinase inhibitor
    Nafissi, Nellie N.
    Karlin, Nina
    Pittelkow, Mark R.
    Dicaudo, David J.
    Mangold, Aaron R.
    ANTI-CANCER DRUGS, 2021, 32 (04) : 474 - 475
12345